Tremis Capital

Tremis Capital is an India-based investor with a presence on LinkedIn and Crunchbase and a website at tremis.in, but the public record shared here lacks stage, check size, or any explicit healthcare commitment. The .in domain and India LinkedIn registration place it inside one of the world’s most active digital health and health-services markets, which is meaningful context for founders building for Indian payers, providers, or pharma. Without a stated thesis, founders should assume Tremis is a generalist seed-to-Series A platform rather than a clinical-grade life-sciences specialist, and treat any healthcare engagement as opportunistic rather than mandate-driven. AI-first founders building automation, RCM, diagnostics workflow, or consumer health products targeting India would be the most natural fit; deep-tech bio, regulated devices needing FDA pathways, or companies that need a US healthcare-experienced board partner should look at sector specialists in their geography. Check size cannot be inferred reliably from the data provided, but Indian generalist micro and seed funds typically write USD 250K to USD 2M tickets, so plan accordingly. The most realistic entry path is a warm intro through a portfolio founder or a LinkedIn message to an associate or partner with a tight summary of traction, a specific Indian-market wedge, and clear ask. Founders should request the firm’s stage and sector preferences upfront before investing pitching time, since the absence of a stated healthcare AI program means there is real risk of a pleasant but inconclusive process.